The 17 identified targets are central to the druggable aspects of the tumor microenvironment; anti-PDGFR approaches, LOXL2 inhibitors, MMP14 targeting, and FAP are well-studied strategies in GC treatment. The gene discussed is LOXL2; the disease is neoplasm.